BotImage™, Inc is a medical imaging software company that utilizes artificial intelligence technology for magnetic resonance imaging interpretation. BotImage is a subsidiary of ScanMed®, LLC, an established medical device company specializing in MRI hardware, prostate cancer detection, and COPD functional lung imaging with the intent of bringing highly accurate MRI interpretation software to physicians.
BotImage’s software interprets multi-parametric and bi-parametric MRI using random f0rest with instance weight and MR segmentation by deep learning with holistically-nested networks. Our first product, ProstatID™ utilizes proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, correlation data, and first-pass AI interpretations to aid in the early diagnosis of prostate cancer.
BotImage™, Inc will bring prostate cancer early detection with MRI and AI to the forefront of medicine with ProstatID™. Our highly advanced, non-invasive technology shows promise of delivering high 90th percentile sensitivity in detection, as well as, specificity (accuracy) with the near elimination of false positives and false negatives. Once refined, we will then utilize the same baseline AI algorithms to address the early diagnosis of other cancers and COPD.